HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.

Abstract
The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors (SSRIs) have been used more frequently. In the present study, the efficacy and side-effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM-III-R were randomly assigned to two subgroups; citalopram (n = 36) or moclobemide (n = 35). The study was an 8-week, randomized, open-label, rater-blinded, parallel-group trial. All patients were assessed by Hamilton anxiety rating (HAM-A), Liebowitz social anxiety (LSAS), clinical global impression-severity of illness (CGI-SI) and clinical global impression-improvement (CGI-I) scales. There was a similar percentage of responders (citalopram 75%, n = 27 and moclobemide 74.3%, n = 26), with a >50% or greater reduction in LSAS total score and ratings of "very much" or "much improved" on the CGI-I. None of the patients withdrew from the study. The results of the present study suggest that citalopram has shown promising results in patients with SP.
AuthorsMurad Atmaca, Murat Kuloglu, Ertan Tezcan, Ahmet Unal
JournalHuman psychopharmacology (Hum Psychopharmacol) Vol. 17 Issue 8 Pg. 401-5 (Dec 2002) ISSN: 0885-6222 [Print] England
PMID12457375 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
CopyrightCopyright 2002 John Wiley & Sons, Ltd.
Chemical References
  • Monoamine Oxidase Inhibitors
  • Serotonin Uptake Inhibitors
  • Citalopram
  • Moclobemide
Topics
  • Adolescent
  • Adult
  • Citalopram (adverse effects, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Moclobemide (adverse effects, therapeutic use)
  • Monoamine Oxidase Inhibitors (adverse effects, therapeutic use)
  • Phobic Disorders (drug therapy, psychology)
  • Psychiatric Status Rating Scales
  • Selective Serotonin Reuptake Inhibitors (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: